Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (2016 - 2026)

Corvus Pharmaceuticals' Shares Outstanding history spans 12 years, with the latest figure at $84.1 million for Q1 2026.

  • Quarterly Shares Outstanding rose 23.35% to $84.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $84.1 million through Mar 2026, up 23.35% year-over-year, with the annual reading at $74.7 million for FY2025, 10.01% up from the prior year.
  • Shares Outstanding came in at $84.1 million for Q1 2026, up from $74.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $84.1 million in Q1 2026 to a low of $46.6 million in Q1 2022.
  • The 5-year median for Shares Outstanding is $49.0 million (2023), against an average of $58.7 million.
  • Year-over-year, Shares Outstanding changed 0.0% in 2022 and then skyrocketed 39.01% in 2025.
  • Corvus Pharmaceuticals' Shares Outstanding stood at $46.6 million in 2022, then increased by 5.34% to $49.0 million in 2023, then soared by 38.46% to $67.9 million in 2024, then rose by 10.01% to $74.7 million in 2025, then rose by 12.58% to $84.1 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Shares Outstanding are $84.1 million (Q1 2026), $74.7 million (Q4 2025), and $74.7 million (Q3 2025).